Views & Analysis Coming of age: Alnylam and the RNAi revolution Alynylam has a crucial two years ahead of it, but it and RNAi could be about to come of age.
News AZ claims EU approval for new Calquence regimens in CLL AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, currently facing a strong challenge from BeOne's rival Brukinsa.
